X4 Pharmaceuticals (XFOR) Income from Continuing Operations (2017 - 2025)
X4 Pharmaceuticals posted quarterly Income from Continuing Operations of 23925000.0 for Q4 2025, up 39.92% year-on-year from 17099223.31 in Q4 2024, and up 19.76% on a QoQ basis from 29815000.0 in Q3 2025.
X4 Pharmaceuticals (XFOR) has 9 years of Income from Continuing Operations data on file, last reported at 23925000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations rose 39.92% year-over-year to 23925000.0; the trailing twelve-month figure through Dec 2025 stood at 79199000.0 (down 111.48% YoY), and the FY2025 full-year result was 79199000.0, down 111.48% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 23925000.0, up from 29815000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 90833000.0 in Q2 2024 and bottomed at 55712000.0 in Q2 2023.
- The 5-year median for Income from Continuing Operations is 22945000.0 (2022), against an average of 20018950.0.
- Peak annual rise in Income from Continuing Operations reached 263.04% in 2024, while the deepest fall reached 1492.02% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 30207000.0 in 2021, then grew by 3.65% to 29104000.0 in 2022, then soared by 34.27% to 19130000.0 in 2023, then plunged by 108.16% to 39821000.0 in 2024, then soared by 39.92% to 23925000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 23925000.0 (Q4 2025), 29815000.0 (Q3 2025), and 25741000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | X4 Pharmaceuticals | 182.28 Mn | 182.28 Mn | 2.20 Mn | -23.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23.93 Mn |
| Sep 30, 2025 | -29.82 Mn |
| Jun 30, 2025 | -25.74 Mn |
| Mar 31, 2025 | 282,000.00 |
| Dec 31, 2024 | -39.82 Mn |
| Sep 30, 2024 | -36.70 Mn |
| Jun 30, 2024 | 90.83 Mn |
| Mar 31, 2024 | -51.77 Mn |
| Dec 31, 2023 | -19.13 Mn |
| Sep 30, 2023 | -2.31 Mn |
| Jun 30, 2023 | -55.71 Mn |
| Mar 31, 2023 | -24.02 Mn |
| Dec 31, 2022 | -29.10 Mn |
| Sep 30, 2022 | -21.59 Mn |
| Jun 30, 2022 | -21.21 Mn |
| Mar 31, 2022 | -21.97 Mn |
| Dec 31, 2021 | -30.21 Mn |
| Sep 30, 2021 | -20.18 Mn |
| Jun 30, 2021 | -19.64 Mn |
| Mar 31, 2021 | -18.68 Mn |
| Dec 31, 2020 | -18.40 Mn |
| Sep 30, 2020 | -17.45 Mn |
| Jun 30, 2020 | -15.14 Mn |
| Mar 31, 2020 | -11.14 Mn |
| Dec 31, 2019 | -10.84 Mn |
| Sep 30, 2019 | -17.71 Mn |
| Jun 30, 2019 | -13.38 Mn |
| Mar 31, 2019 | -10.87 Mn |
| Dec 31, 2018 | -8.24 Mn |
| Sep 30, 2018 | -8.64 Mn |
| Jun 30, 2018 | -6.48 Mn |
| Mar 31, 2018 | -6.21 Mn |
| Dec 31, 2017 | 3.57 Mn |
| Sep 30, 2017 | -13.31 Mn |
| Jun 30, 2017 | -6.09 Mn |
| Mar 31, 2017 | -6.85 Mn |